MOR vs. SRPT, PCVX, QGEN, ROIV, ASND, RVMD, BPMC, LEGN, AXSM, and TLX
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry.
MorphoSys vs.
Sarepta Therapeutics (NASDAQ:SRPT) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation.
Sarepta Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
In the previous week, Sarepta Therapeutics had 13 more articles in the media than MorphoSys. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 0 mentions for MorphoSys. Sarepta Therapeutics' average media sentiment score of 0.99 beat MorphoSys' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.
Sarepta Therapeutics has a net margin of 7.43% compared to MorphoSys' net margin of -226.79%. Sarepta Therapeutics' return on equity of 11.00% beat MorphoSys' return on equity.
86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Sarepta Therapeutics presently has a consensus price target of $176.77, suggesting a potential upside of 66.33%. MorphoSys has a consensus price target of $18.25, suggesting a potential downside of 3.74%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than MorphoSys.
MorphoSys has lower revenue, but higher earnings than Sarepta Therapeutics. MorphoSys is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics received 1439 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 75.23% of users gave Sarepta Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
Summary
Sarepta Therapeutics beats MorphoSys on 16 of the 19 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
This page (NASDAQ:MOR) was last updated on 2/21/2025 by MarketBeat.com Staff
